CMS — CMS Energy Corporation

The tape and the news flow both lean negative. CMS is down 1.9% over one week, 4.1% over one month, 8.7% over three months and 13.7% over six months as of 2026-09-13, and it is trading at the very bottom of its 52-week range after a Q2 2026 adjusted EPS print of $0.37-$0.39 that missed consensus on unfavorable weather comparisons and storm-related costs. BMO trimmed its price target from $82 to $77 (still Outperform), and elevated rates continue to cap utility multiples. The offsetting positives - 3.2% dividend yield, reaffirmed guidance, a >93% institutional ownership base with CalSTRS adding, and a consensus Buy rating with a $80.38 average target - are not yet enough to change the direction of the tape.

Revenue inflected up hard through 2025 into Q1 2026, then stalled: +15.9% YoY in Q3'25 ($2,021M vs $1,743M), +12.3% in Q4'25 ($2,233M vs $1,989M), +11.6% in Q1'26 ($2,730M, the highest quarter in the 12-quarter window, vs $2,447M), then -0.5% in Q2'26 ($1,829M vs $1,838M). Earnings tell a worse short-term story: diluted EPS went 0.84 (Q3'24) → 0.88 (Q4'24) → 1.01 (Q1'25) → 0.66 (Q2'25) → 0.92 (Q3'25) → 0.94 (Q4'25) → 1.13 (Q1'26) → 0.39 (Q2'26). Q2 2026 was the first clear YoY EPS decline in the visible window (-41%), and H1 2026 EPS of $1.52 is down 9.0% from H1 2025's $1.67. Operating margin has compressed in three of the last four quarters (Q2'26 14.4% vs Q2'25 17.2%; Q1'26 17.9% vs 20.2%; Q4'25 19.5% vs 21.4%), with only Q3'25 expanding (23.8% vs 21.1%). The critical arithmetic: to hit the FY26 guidance midpoint of $3.865, H2 2026 must deliver ~$2.35 of EPS versus $1.86 in H2 2025 - roughly +26% YoY. That is a genuine back-half ramp requirement, not a rounding error, and it is the single most important number in this dataset. Verdict: revenue growth decelerating to flat, margins compressing, and EPS structurally back-half weighted - a recent-fundamental blip that still has to prove itself in Q3, not yet a proven multi-year deterioration, but not a clean blip either.

Mixed depending on which lens you use, which is why the stock looks cheaper than it is on some screens. As of 2026-09-13, at $67.15, the trailing P/E is 19.9x (FMP) versus CMS's own 5-year average trailing P/E of 19.06x - i.e. the trailing multiple has actually EXPANDED despite the stock sitting at a 52-week low, because earnings fell faster than the price. P/S of 2.39x is dead in line with the 5-year average of 2.41x, and P/B of 2.07x is not cheap for a regulated utility. But on forward numbers the picture flips: $67.15 divided by next-FY consensus EPS of $3.871 is 17.35x, and divided by management's 2027 guidance midpoint of $4.125 it is 16.28x - both below the 17-19x range the stock has historically carried and below the 19.5x implied by the $80.38 sell-side consensus target. The 3.17% dividend yield is covered by a ~55% payout on 2026 guidance EPS. Bottom line: fair on trailing earnings, modestly cheap on forward earnings and the own-history forward comparison. The PEG ratio of -67.3 in the data is a statistical artifact of near-zero/negative trailing growth and should be ignored entirely.

The market is not paying up for growth that has not shown up - on the contrary, it is discounting the growth. At $67.15 you are paying 16.3x 2027 guidance EPS for a company that management insists can compound 6-8%. That is a skeptical multiple. What the price is actually embedding: (1) doubt that H2 2026 can produce ~+26% YoY EPS growth after H1 came in 9% below last year, (2) storm-cost recovery and rate-case timing uncertainty in Michigan, and (3) rate-driven multiple compression for the whole sector. If Q3 2026 (late October) confirms the back-half ramp and the NorthStar exit stays on schedule, the current multiple is too low and the gap to the $80.38 consensus target closes. If Q3 misses again, guidance gets cut and the stock re-rates down from ~17x to 15-16x forward - which on $3.60-3.70 of revised EPS is a $54-$59 stock. That asymmetry, not the dividend, is what you are underwriting here.

Clean, unbroken downtrend with no reversal signal. As of 2026-09-13: RSI(14) at 31.5, just above the oversold line but showing no bullish divergence; price of $67.15 sits below the 20-day SMA (implied ~$68.91, -2.55%), the 50-day SMA (~$71.61, -6.23%) and the 200-day SMA (~$73.42, -8.54%) - a textbook bearish stack with all three averages overhead and the 200-day still descending. The stock is effectively at its 52-week low ($67.15 vs $67.00), which means there is no visible support shelf to trade against. A beta of 0.331 means CMS will not get much help from a market rally. Entry-timing implication: RSI near 30 inside a persistent downtrend is a knife-catch, not a buy signal. The first genuine confirmation would be reclaiming the 20-day SMA around $69 plus RSI back above 40 - or, more reliably, a clean Q3 print in late October. There is no technical reason to be early here.

• Interest rates remain the dominant swing factor: utilities are bond proxies, and higher-for-longer rates both compress the multiple CMS can command and raise the cost of the debt and equity it must continuously issue to fund capex.
• Michigan Public Service Commission regulation: rate case outcomes and storm-cost recovery timing are the biggest determinants of whether CMS hits the high end of its 6-8% long-term EPS growth target.
• Data center and large industrial load growth: a real multi-year demand tailwind that management is actively courting through large-load tariffs, but it remains contingent on local zoning and IRP proceedings rather than booked revenue.
• Clean energy buildout mandates: the newly filed 20-year IRP targets 15.8 GW of clean energy and 4.1 GW of battery storage by 2040, and a federal court striking down the DOE order delaying a Michigan coal retirement brings clarity - but it also means a sustained, capital-hungry construction program.
• Sector rotation and defensive underperformance: in a market rewarding growth and AI infrastructure, a 0.33-beta regulated utility with a 3.2% yield is easy to ignore, which is part of why the stock has bled 13.7% over six months.

• Q3 2026 earnings in late October 2026 - the single most important data point, since it tests whether the ~+26% YoY H2 EPS ramp needed to hit $3.83-$3.90 guidance is real or aspirational.
• Progress and disclosure on the NorthStar Clean Energy exit, which management says cuts parent funding needs by more than $500M through 2030 and moves CMS to nearly 100% rate-base earnings after 2027.
• Michigan Public Service Commission decisions on pending rate cases and storm-cost recovery, which directly bridge the gap between actual H1 earnings and full-year guidance.
• Ongoing 20-year IRP proceedings and approvals of large-load data center tariffs, which would convert a demand narrative into contracted, rate-base-backed revenue.
• Any Fed rate cuts - a sector-wide re-rating catalyst that would likely lift CMS's multiple even without company-specific news, given the leverage and yield sensitivity.

• H2 2026 execution risk is the headline risk: after H1 EPS of $1.52 (-9% YoY), CMS needs roughly $2.35 in H2 versus $1.86 a year ago to hit the guidance midpoint - a ~26% YoY ramp that a second consecutive miss would likely invalidate.
• Persistently negative free cash flow: -$345M in Q2'26 and negative in 9 of the last 12 quarters, cumulatively roughly -$3.5B over that span, funded by debt (long-term debt up from $14.12B at Q3'23 to $18.17B at Q2'26) and equity issuance, which dilutes shareholders and magnifies rate sensitivity.
• Regulatory and storm-cost recovery risk at the MPSC - adverse rulings on capital cost recovery or reliability spending would hit both earnings and the growth narrative simultaneously.
• Balance-sheet leverage of 1.98x debt/equity on $18.17B of long-term debt against $9.77B of equity, with a current ratio of 0.92 and only $241M of cash - thin liquidity for a company with a ~$4B annual capex program.
• Valuation risk if the growth story breaks: the trailing P/E of 19.9x is already above the 5-year average of 19.06x, so there is little multiple cushion - a guidance cut would compress the multiple and the earnings estimate at the same time.

CMS is a decent, boring regulated utility with a 3.2% dividend yield, a credible 6-8% EPS growth runway, a supportive Michigan regulatory framework and a real data center demand optionality story - but it is not a buy today. H1 2026 EPS is down 9% YoY, Q2 missed, and the company needs a ~26% YoY H2 EPS ramp to hit reaffirmed guidance; the market at 16.3x 2027 guidance is right to discount that, not wrong. The price is close to fair (my calculated intrinsic value is around $73), the technicals are in an unbroken downtrend at the 52-week low, and the Q3 print in late October is a genuine binary. This is a watch-list name with a specific trigger: confirm the H2 ramp at Q3, or let the stock reclaim its 20-day moving average, before treating the 20% gap to the $80.38 consensus target as free money. Below $67 with confirmation, the risk/reward flips attractive quickly; without confirmation, the value trap risk is real.

Justified forward-P/E approach: applied 18.9x - a deliberate discount to CMS's own 5-year average trailing P/E of 19.06x, reflecting a higher-for-longer rate environment plus the H2-2026 execution risk the data reveals - to next-FY consensus EPS of $3.871, giving $73.16; cross-checked with 17.75x on management's 2027 guidance midpoint of $4.125, giving $73.22. Settled at $73.20, roughly 9% above the 2026-09-13 price of $67.15 before the 3.2% dividend, and deliberately below the $80.38 sell-side consensus target, which implies a fuller 19.5x multiple.